<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">RUDN Journal of Medicine</journal-id><journal-title-group><journal-title xml:lang="en">RUDN Journal of Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российского университета дружбы народов. Серия: Медицина</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-0245</issn><issn publication-format="electronic">2313-0261</issn><publisher><publisher-name xml:lang="en">Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">21283</article-id><article-id pub-id-type="doi">10.22363/2313-0245-2019-23-1-70-78</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>IMMUNOLOGY. ALLERGOLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ИММУНОЛОГИЯ. АЛЛЕРГОЛОГИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">THE MAIN CLINICAL SYNDROMES ASSOCIATED WITH ACTIVE CRONIC ATIPICAL EPSTEINE-BARR VIRUS INFECTION: CREATED ALGORITHM OF CLINICAL AND LABORATORY DIAGNOSTIC</article-title><trans-title-group xml:lang="ru"><trans-title>ОСНОВНЫЕ КЛИНИЧЕСКИЕ СИНДРОМЫ, АССОЦИИРОВАННЫЕ С АТИПИЧНОЙ ХРОНИЧЕСКОЙ АКТИВНОЙ ИНФЕКЦИЕЙ, ВЫЗЫВАЕМОЙ ВИРУСОМ ЭПШТЕЙНА-БАРР. РАЗРАБОТКА АЛГОРИТМА КЛИНИЧЕСКОЙ И ЛАБОРАТОРНОЙ ДИАГНОСТИКИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="spin">4714-2488</contrib-id><name-alternatives><name xml:lang="en"><surname>Nesterova</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Нестерова</surname><given-names>И. В.</given-names></name></name-alternatives><email>inesterova1@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="spin">2813-4952</contrib-id><name-alternatives><name xml:lang="en"><surname>Khalturina</surname><given-names>E. O.</given-names></name><name xml:lang="ru"><surname>Халтурина</surname><given-names>Е. О.</given-names></name></name-alternatives><email>inesterova1@yandex.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kuban State Medical University</institution></aff><aff><institution xml:lang="ru">Кубанский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Clinical and diagnostic center MEDSI on Belorusskaya</institution></aff><aff><institution xml:lang="ru">Клинико-диагностический центр МЕДСИ на Белорусской</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Moscow (Sechenov University)</institution></aff><aff><institution xml:lang="ru">Первый московский медицинский университет им. И.М. Сеченова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2019</year></pub-date><volume>23</volume><issue>1</issue><issue-title xml:lang="en">VOL 23, NO1 (2019)</issue-title><issue-title xml:lang="ru">ТОМ 23, №1 (2019)</issue-title><fpage>70</fpage><lpage>78</lpage><history><date date-type="received" iso-8601-date="2019-06-12"><day>12</day><month>06</month><year>2019</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Nesterova I.V., Khalturina E.O.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, Нестерова И.В., Халтурина Е.О.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Nesterova I.V., Khalturina E.O.</copyright-holder><copyright-holder xml:lang="ru">Нестерова И.В., Халтурина Е.О.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.rudn.ru/medicine/article/view/21283">https://journals.rudn.ru/medicine/article/view/21283</self-uri><abstract xml:lang="en"><p>The annual steady increase of the herpesviral infections number in the human population is one of the most important interdisciplinary problems of modern medicine. Clinicians and laboratory diagnostics physicians face difficulties in clinical symptoms assessing, inadequate laboratory diagnostics and difficulties in interpretation of the obtained results. This is connected with a low awareness of atypical chronic active infection symptoms caused in particular by the Epstein-Barr virus (EBV), of the ability to fully diagnose, and of serious consequencescaused by prolonged activity of herpesviruses in the human body. Studies were carried out to determinethe functioning features of the antiviral defense system, as well as defects and disorders in the interferon system in patients suffering from various mono-, mixed herpesvirus infections and bacterial co-infections. The main clinical syndromes associated with these herpetic infections, as well as prevailing nosological forms of concomitant diseases, have been identified. Among the group of patients suffering from mono-herpesvirus infections, the leading position takes the allergic syndrome (55%), while the syndrome of chronic fatigue syndrome (85%) and the infectious syndrome (68%) prevail in the incidence of patients with mixed herpesvirus infections. Extended testing of the antiviral protection main mechanisms state made it possible to identify the most frequent defects in the functioning of antiviral immunity: disturbances in induced production of IFNα and IFNγ, deficiency of cytotoxic T lymphocytes, deficiency of natural killer cells, including EKT, and / or inadequate absence of their activation, neutropenia. The revealed clinical syndromes and functioning features of the antiviral defense system will allow us to further develop the concept of complex, individualized, etio- and immunopathogenetic therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Неуклонный рост числа заболеваний, ассоциированных с герпесвирусными инфекциями, является одной из актуальных междисциплинарных проблем современной медицины. Разнообразие клинических и лабораторных «масок» этих инфекций представляет большие сложности в интерпретации полученных клинико-анамнестических и лабораторных данных, а также результатов объективного осмотра пациентов. Это связано с низкой осведомленностью врачей о наличии атипичных хронических активных форм этих инфекций, вызываемых в частности вирусом Эпштейна-Барр, которые затрудняют постановку диагноза и приводят к серьезным последствиям, связанным с персистированием вирусов в организме человека. Проведены исследования особенностей функционирования системы противовирусной защиты, а также дефекты и нарушения в системе интерферонов у пациентов, страдающих различными моно-, микст-герпесвирусными инфекциями и бактериальными ко-инфекциями. Выявлены основные клинические синдромы, ассоциированные с этими герпетическим инфекциям, а также превалирующие нозологические формы сопутствующих заболеваний. Среди группы пациентов, страдающих моно-герпесвирусными инфекциями лидирующее положение занимает аллергический синдром (55%), в то время как в структуре заболеваемости пациентов с микст-герпесвирусными инфекциями превалируют синдром хронической усталости (85%) и инфекционный синдром (68%). Расширенное тестирование состояния основных механизмов противовирусной защиты, позволило выявить наиболее часто встречающиеся дефекты функционирования противовирусного иммунитета: нарушения индуцированной продукции ИФНα и ИФНγ, дефицит цитотоксических Т лимфоцитов, дефицит естественных киллерных клеток, в т.ч. ЕКТ, и/или неадекватное отсутствие их активации, нейтропению. Выявленные клинические синдромы и особенности функционирования системы противовирусной защиты позволят в дальнейшем разработать концепцию комплексной, индивидуализированной, этио- и иммунопатогенетической терапии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>herpesvirus infection</kwd><kwd>antiviral defense</kwd><kwd>interferon</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>герпесвирусная инфекция</kwd><kwd>противовирусная защита</kwd><kwd>интерферон</kwd><kwd>вирус Эпштейна-Барр</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Babcock J.G., Hochberg D., Thorley-Lawson A.D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity. 2000.13: 497-506.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Hislop A.D., Taylor G.S., Sauce D., Rickinson A.B. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007. 25. P. 587-617.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kuzushima K., Matsuoka H. Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection. J Med Virol. 2001.64:141-8.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Lusso P. HHV-6 and the immune system: Mechanisms of immunomodulation and viral escape. J ClinVirol. 2006. 37(Suppl 1):S4-10.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Merlo A., Turrini R., Dolcetti R., Martorelli D., Muraro E., Comoli P., Rosato A. The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica. 2010. 95 (10). P. 1769-1777.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ning S. Innate immune modulation in EBV infection. Herpesviridae. 2010. 2 (1). P. 1.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Pizzigallo Eligio, Racciatti Delia, and Gorgoretti Valeria. EBV Chronic Infections. Mediterr J Hematol Infect Dis. 2010. 2 (1).</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Randall R.E., Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J. Gen.Virol. 2008. 89. P. 1-47.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Wu L., Fossum E., Joo C.H., Inn K.S., Shin Y.C., Johannsen E., Hutt-Fletcher L.M., Hass J., Jung J.U. Epstein-Barr virus LF2: an antagonist to type I interferon. J Virol. 2009. 83 (2). P. 1140-1146.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Vorobiev A.A., Kiselevskiy M.V., Khalturina E.O. Immune system. Immunology. 2001. № 6. P. 15.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Tracy S.I., Kalacheva K., Lunemann J.D., Luzuiaga K. et al. Persistence of Epstein-Barr virus in self-reactive memory B cells. J. Viorol. 2012. Vol. 88. № 22. P. 12330-12340.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Olson D., Huntington M.K. Co-infections with cytomegalovirus and Epstein-Barr virus in mononucleosis: case report and review of literature. S D Med. 2009. V. 62. № 9. P. 351-353.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Xia Wang et al. Coinfection with EBV/CMV and other respiratory agents in children with suspected infectious mononucleosis. Virol. J. 2010. V. 7. P. 247.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Bravender T. Epstein-Barr virus, cytomegalovirus, and infectious mononucleosis. Adolesc. Med. State Art Rev. 2010. V. 21. № 2. P. 251-264.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ulish Е.I. Persistence infections and human: relationship strategy. Child health. 2009. № 4. P. 114-122.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>van de Berg P.J.E.J., Griffiths S.J., Yong S.-L., Macaulay R., Jackson S., Henson S.M., ten Berge I.J.M., Akbar A.N., van Lier A.W. Cytomegalovirus Infection Reduces Telomere. J. Immunol. 2010. 184:3417-3423.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Poon S.S., Lansdorp P.M. Current Protocols in Cell Biology. 2001. 12:18.4:18.4.1-18.4.21.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Fukumoto H., Kanno T., Hasegawa H., Katano H. Pathology of Kaposi’s sarcoma-associated herpesvirus infection. 2010. Front Microbiol 2: 175.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Kutok J., Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Patholю 2006. P. 375-404.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Levin L., Munger K., O’Reilly E., Falk K., Ascherio A. Primary infection with Epstein-Barr virus and risk of multiple sclerosis. AnnNeurol. 2010. 67: 824-830.</mixed-citation></ref></ref-list></back></article>
